Percutaneous Coronary Intervention of Functionally Nonsignificant Stenosis5-Year Follow-Up of the DEFER Study
Nico H.J. Pijls, MD, PhD*,*,
Pepijn van Schaardenburgh, MD*,
Ganesh Manoharan, MD ,
Eric Boersma, PhD ,
Jan-Willem Bech, MD, PhD*,
Marcel van't Veer, MSc*,
Frits Bär, MD, PhD ,
Jan Hoorntje, MD, PhD||,
Jacques Koolen, MD, PhD*,
William Wijns, MD, PhD and
Bernard de Bruyne, MD, PhD
* Catharina Hospital Eindhoven, Eindhoven, the Netherlands
Cardiovascular Center Aalst, Aalst, Belgium
Thoraxcentrum Rotterdam, Rotterdam, the Netherlands
Academic Hospital Maastricht, Maastricht, the Netherlands
|| Isala Clinics Zwolle, Zwolle, the Netherlands.
View larger version (32K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Flowchart of the Study, Randomization, and Definition of the 3 Groups
To avoid bias, randomization was performed before the physiologic measurement (see text). DEFER = deferral of percutaneous coronary intervention; FFR = fractional flow reserve; PCI = percutaneous coronary intervention; PERFORM = performance of percutaneous coronary intervention; REFERENCE = percutaneous coronary intervention anyway because of ischemic fractional flow reserve.
|
|
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Survival and Adverse Events
(Top) Kaplan-Meier survival curves for freedom from adverse cardiac events during 5 years follow-up for the 3 groups. (Middle) Cardiac death and acute myocardial infarction rate in the 3 groups after a follow-up of 5 years. (Bottom) Percentage of patients free from chest pain in the 3 groups at baseline and during follow-up. *p = 0.028; **p = <0.001; ***p = 0.021. MI = myocardial infarction; other abbreviations as in Figure 1.
|
|
|
